

Elaine T Lam

List of Publications by Citations

Source: <https://exaly.com/author-pdf/300997/elaine-t-lam-publications-by-citations.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

44
papers

1,818
citations

18
h-index

42
g-index

47
ext. papers

2,349
ext. citations

5.2
avg. IF

3.99
L-index

#	Paper	IF	Citations
44	Kidney Cancer, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2017 , 15, 804-834	7.3	320
43	Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer. <i>Journal of Clinical Oncology</i> , 2010 , 28, 2323-30	2.2	313
42	Phase I Dose-Escalation Trial of PT2385, a First-in-Class Hypoxia-Inducible Factor-2 Antagonist in Patients With Previously Treated Advanced Clear Cell Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2018 , 36, 867-874	2.2	198
41	Kidney cancer, version 3.2015. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015 , 13, 151-9	7.3	166
40	NCCN Guidelines Insights: Kidney Cancer, Version 2.2020. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019 , 17, 1278-1285	7.3	118
39	Testicular Cancer, Version 2.2015. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015 , 13, 772-99	7.3	87
38	Cabozantinib in advanced non-clear-cell renal cell carcinoma: a multicentre, retrospective, cohort study. <i>Lancet Oncology, The</i> , 2019 , 20, 581-590	21.7	81
37	NCCN Guidelines Insights: Kidney Cancer, Version 1.2021. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020 , 18, 1160-1170	7.3	59
36	Renal cell carcinoma: a review of biology and pathophysiology. <i>F1000Research</i> , 2018 , 7, 307	3.6	56
35	Kidney cancer, version 2.2014. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2014 , 12, 175-82	7.3	43
34	Phase I study of oral rigosertib (ON 01910.Na), a dual inhibitor of the PI3K and Plk1 pathways, in adult patients with advanced solid malignancies. <i>Clinical Cancer Research</i> , 2014 , 20, 1656-65	12.9	43
33	Local control rates of metastatic renal cell carcinoma (RCC) to the bone using stereotactic body radiation therapy: Is RCC truly radioresistant?. <i>Practical Radiation Oncology</i> , 2015 , 5, e589-e596	2.8	40
32	SWOG S0925: A Randomized Phase II Study of Androgen Deprivation Combined With Cixutumumab Versus Androgen Deprivation Alone in Patients With New Metastatic Hormone-Sensitive Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2015 , 33, 1601-8	2.2	38
31	Oncolytic reovirus in combination with chemotherapy in metastatic or recurrent non-small cell lung cancer patients with KRAS-activated tumors. <i>Cancer</i> , 2016 , 122, 875-83	6.4	33
30	Local Control Rates of Metastatic Renal Cell Carcinoma (RCC) to Thoracic, Abdominal, and Soft Tissue Lesions Using Stereotactic Body Radiotherapy (SBRT). <i>Radiation Oncology</i> , 2015 , 10, 218	4.2	32
29	Safety and Efficacy of Nivolumab in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma: Results From the Phase IIIb/IV CheckMate 374 Study. <i>Clinical Genitourinary Cancer</i> , 2020 , 18, 461-468.e3	3.3	24
28	Kidney Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology.. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2022 , 20, 71-90	7.3	20

27	Phase I trial of non-cytotoxic suramin as a modulator of docetaxel and gemcitabine therapy in previously treated patients with non-small cell lung cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2010 , 66, 1019-29	3.5	18
26	Phase I dose escalation study of KOS-1584, a novel epothilone, in patients with advanced solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2012 , 69, 523-31	3.5	14
25	Loss of MAP3K7 Sensitizes Prostate Cancer Cells to CDK1/2 Inhibition and DNA Damage by Disrupting Homologous Recombination. <i>Molecular Cancer Research</i> , 2019 , 17, 1985-1998	6.6	11
24	Retrospective analysis of the safety and efficacy of high-dose interleukin-2 after prior tyrosine kinase inhibitor therapy in patients with advanced renal cell carcinoma. <i>Journal of Immunotherapy</i> , 2014 , 37, 360-5	5	11
23	Patient characterization and usage trends of proton beam therapy for localized prostate cancer in the United States: A study of the National Cancer Database. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017 , 35, 438-446	2.8	10
22	Patient-Reported Outcomes from the Phase III Randomized IMmotion151 Trial: Atezolizumab Versus Sunitinib in Treatment-Naïve Metastatic Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2020 , 26, 2506-2514	12.9	10
21	Phase I Study of Enavatuzumab, a First-in-Class Humanized Monoclonal Antibody Targeting the TWEAK Receptor, in Patients with Advanced Solid Tumors. <i>Molecular Cancer Therapeutics</i> , 2018 , 17, 215-221	6.1	9
20	A phase I study of gefitinib, capecitabine, and celecoxib in patients with advanced solid tumors. <i>Molecular Cancer Therapeutics</i> , 2008 , 7, 3685-94	6.1	8
19	Pharmacokinetic drug-drug interaction study of the angiopoietin-1/angiopoietin-2-inhibiting peptibody trebananib (AMG 386) and paclitaxel in patients with advanced solid tumors. <i>Investigational New Drugs</i> , 2015 , 33, 691-9	4.3	7
18	Patient-reported outcomes in a phase 2 study comparing atezolizumab alone or with bevacizumab vs sunitinib in previously untreated metastatic renal cell carcinoma. <i>BJU International</i> , 2020 , 126, 73-82	5.6	7
17	Clinical significance of sunitinib-associated macrocytosis in metastatic renal cell carcinoma. <i>Cancer Medicine</i> , 2016 , 5, 3386-3393	4.8	6
16	Clinical Activity and Safety of Cabozantinib for Brain Metastases in Patients With Renal Cell Carcinoma. <i>JAMA Oncology</i> , 2021 ,	13.4	6
15	Does the Renal Parenchyma Adjacent to the Tumor Contribute to Kidney Function? A Critical Analysis of Glomerular Viability in Partial Nephrectomy Specimens. <i>Urology</i> , 2016 , 87, 114-9	1.6	5
14	Phase II Trial of Acai Juice Product in Biochemically Recurrent Prostate Cancer. <i>Integrative Cancer Therapies</i> , 2018 , 17, 1103-1108	3	5
13	A Cost-Effectiveness Analysis of Nivolumab Plus Ipilimumab Versus Pembrolizumab Plus Axitinib and Versus Avelumab Plus Axitinib in First-Line Treatment of Advanced Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2021 , 19, 370-370.e7	3.3	3
12	Collision renal cell papillary and medullary carcinoma in a 66-year-old man. <i>Oncology</i> , 2013 , 27, 893, 896, 898	1.8	3
11	Preclinical and Dose-Finding Phase I Trial Results of Combined Treatment with a TORC1/2 Inhibitor (TAK-228) and Aurora A Kinase Inhibitor (Alisertib) in Solid Tumors. <i>Clinical Cancer Research</i> , 2020 , 26, 4633-4642	12.9	2
10	Evaluation of fosaprepitant-associated hypersensitivity reactions at a National Cancer Center. <i>Journal of Oncology Pharmacy Practice</i> , 2020 , 26, 1369-1373	1.7	2

9	Neoadjuvant and adjuvant hormonal and chemotherapy for prostate cancer. <i>Hematology/Oncology Clinics of North America</i> , 2013 , 27, 1189-204, viii	3.1	2
8	Tumor flare of brain metastases upon dose interruption of sunitinib in a patient with metastatic renal cell carcinoma. <i>Cancer Treatment and Research Communications</i> , 2021 , 27, 100367	2	2
7	Do we need skin toxicity? Association of immune checkpoint inhibitor and tyrosine kinase inhibitor-related cutaneous adverse events with outcomes in metastatic renal cell carcinoma. <i>International Journal of Dermatology</i> , 2021 , 60, 1242-1247	1.7	1
6	A phase I pharmacokinetic and safety study of Paclitaxel Injection Concentrate for Nano-dispersion (PICN) alone and in combination with carboplatin in patients with advanced solid malignancies and biliary tract cancers. <i>Cancer Chemotherapy and Pharmacology</i> , 2021 , 87, 779-788	3.5	1
5	A rare case of metastatic renal epithelioid angiomyolipoma. <i>Oncology</i> , 2011 , 25, 832-8	1.8	1
4	Biomarker-Based Phase II Study of Sapanisertib (TAK-228): An mTORC1/2 Inhibitor in Patients With Refractory Metastatic Renal Cell Carcinoma.. <i>JCO Precision Oncology</i> , 2022 , 6, e2100448	3.6	1
3	Metastatic Mature Teratoma and Growing Teratoma Syndrome in Patients with Testicular Non-Seminomatous Germ Cell Tumors. <i>Korean Journal of Radiology</i> , 2021 , 22, 1650-1657	6.9	0
2	Reply to A. Machens et al. <i>Journal of Clinical Oncology</i> , 2010 , 28, e535-e536	2.2	
1	Spontaneous regression of an extragonadal seminomatous germ cell tumor. <i>Cancer Treatment and Research Communications</i> , 2021 , 28, 100383		2